Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides

Thrombosis Research

Volumn 103, Issue 4, 2001, Pages 325-335

  Wall, D ^a   Douglas, S ^a   Ferro, V ^a   Cowden, W ^a   Parish, C ^a  

^a Biology and Environment   (Australia)

Author keywords

Anticoagulant; Antithrombotic; Heparin cofactor II; PI 88; Sulfated oligosaccharide

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; CELLOHEXAOSE SULFATE; CELLOPENTAOSE SULFATE; CELLOTETRAOSE SULFATE; CHITOSAN HEXAMER SULFATE; HEPARIN; HEPARIN COFACTOR II; ISOMALTOHEXAOSE SULFATE; ISOMALTOPENTAOSE SULFATE; LAMINARIHEPTAOSE SULFATE; LAMINARIHEXAOSE SULFATE; LAMINARITETRAOSE SULFATE; LOW MOLECULAR WEIGHT HEPARIN; MALTOHEPTAOSE SULFATE; MALTOHEXAOSE SULFATE; MALTOPENTAOSE SULFATE; MALTOSE SULFATE; MALTOTETRAOSE SULFATE; MALTOTRIOSE SULFATE; MONOSACCHARIDE; OLIGOSACCHARIDE; PHOSPHOMANNOPENTAOSE SULFATE; PI 88; PROTAMINE SULFATE; SUCROSE OCTASULFATE; SULFATE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; CARBOHYDRATE ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; MARMOSET; MOUSE; NONHUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; RAT; REPRODUCIBILITY; SHEEP; SPECIES DIFFERENCE; THROMBOCYTE AGGREGATION;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; ANTITHROMBIN III; BLOOD COAGULATION; DRUG SYNERGISM; HEPARIN; HEPARIN COFACTOR II; HUMANS; OLIGOSACCHARIDES; PARTIAL THROMBOPLASTIN TIME; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFURIC ACID ESTERS; THROMBIN;

EID: 0035880995     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00314-0     Document Type: Article

References (32)

1. Heparin
2. Regulation of thrombin activity by antithrombin and heparin
3. Biosynthesis of heparin and related polysaccharides
4. Clinical applications of new antithrombotic agents
5. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture
6. Activation of heparin cofactor II by dermatan sulfate
7. Glycosaminoglycans and the regulation of blood coagulation
8. Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide
9. Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties
10. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues
11. Characterization of a phosphorylated pentasaccharide isolated from Hansenula holstii NRRL Y-2448 phosphomannan
12. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity
13. Development of a photometric assay for activated partial thromboplastin time and its application to the Cobas Bio centrifugal analyzer
14. Turbidometric determination of prothrombin time by clotting in a centrifugal analyzer
15. Laboratory investigation of platelet function: A review of methodology
16. The euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis
17. Synthesis of sulfated alkyl malto- and laminara-oligosaccharides with potent inhibitory effects on AIDS virus infection
18. Comparative effects of heparin and the sulfatoid GM1474 on coagulation parameters in plasma and blood from various species
19. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II
20. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II
21. Heparin cofactor II Oslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate
22. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II
23. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements
24. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes
25. Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents
26. Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide
27. Influence of hypersulfated lactobionic acid amides on tissue plasminogen activator release
28. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
29. The haemorrhagic and antithrombotic effects of dermatan sulphate
30. Interaction of the sulfated lactobionic acid amide LW 10082 with thrombin and its endogenous inhibitors
31. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082
32. From glycosaminoglycans to heparinoid mimetics with antiproliferative activity